Jump to content
RemedySpot.com

Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia

Rate this topic


Recommended Posts

Guest guest
Posted

BlankRole of CD20 monoclonal antibodies in previously untreated chronic

lymphocytic leukemia.

SA Parikh and WG Wierda

Clin Lymphoma Myeloma Leuk, June 1, 2010; 10 Suppl 1: S27-33.

Department of Leukemia, The University of Texas M. D. Cancer Center,

Houston, TX, USA.

Monoclonal antibodies (MoAbs) directed against the CD20 antigen on B cells have

dramatically altered the treatment landscape for patients with chronic

lymphocytic leukemia (CLL). Rituximab, a chimeric mouse/human MoAb, was the

first antibody to be approved for the treatment of indolent B-cell lymphomas.

Although single-agent, standard-dose rituximab has limited activity as

first-line therapy for patients with CLL, it has synergistic therapeutic

activity when combined with chemotherapy. Indeed, chemoimmunotherapy with

combined fludarabine (F), cyclophosphamide ©, and rituximab was shown to

improve both progression-free and overall survival in a randomized phase III

clinical trial compared with FC in previously untreated patients with CLL. In

this article, we review important clinical trials that have incorporated

rituximab with other agents for treatment-naive patients with CLL. We also

highlight second- and third-generation CD20 MoAbs approved or in development for

the treatment of CLL.

PMID: 20529805

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...